Skip to contentC
CNBX Pharmaceuticals Inc.
C
CNBXCNBX Pharmaceuticals Inc. Q1 2023 · 10-Q
Revenue$0.00$0.00no prior Q1 2022 on file Net Income-$357.67K-$357.67KN/M vs Q1 2022 EPS Diluted-$0.33-$0.33N/M vs Q1 2022 Operating Income-$346,790N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CNBX Pharmaceuticals Inc. · CIK 1343009 · Engraved from SEC EDGAR
ended Nov 30, 2022 · filed Jan 13, 2023 · 44 d after period end